Stem cell transplantation is a cornerstone therapy for various hematologic conditions such as leukemias and myelodysplastic syndromes. Traditionally, the efficacy of cord blood as a source for stem cell transplants has been curtailed by the relatively low number of hematopoietic stem cells available in a single cord blood unit. This cellular deficit often restricts effective engraftment and delays immune reconstitution. Addressing this challenge, the investigators explored a synergistic two-unit transplantation approach combining a single cord blood unit with a laboratory-expanded stem cell product derived from pooled cord blood donations. The phase 2 clinical trial results, recently published in the prestigious Journal of Clinical Oncology, highlight a remarkable one-year survival rate of 96% among 28 participants, with a notably low incidence of severe acute or chronic graft-versus-host disease (GVHD).

One of the study’s principal authors, Dr. Filippo Milano, articulated the unprecedented nature of this transplant modality, emphasizing that patients effectively received cells originating from nine distinct individuals. This intricate cellular mosaic underscores the complex interplay between donor graft components and host immune reconstitution dynamics. Importantly, the adjunctive stem cell product, dubbed dilanubicel and developed under the stewardship of senior author Dr. Colleen Delaney, is constituted from hematopoietic progenitors isolated from six to eight separate cord blood units. These progenitor cells undergo ex vivo expansion to achieve a therapeutically relevant cellular dose before infusion, a technique that marks a significant departure from conventional single-unit transplant paradigms.

The rationale behind utilizing a pooled, expanded progenitor cell product lies in its capacity to provide critical early immune support post-transplant. Although dilanubicel cells do not engraft permanently, their transient presence facilitates rapid hematopoietic recovery. Detailed analysis revealed that by one week post-transplant, patient peripheral blood was predominantly reconstituted by the infused pooled progenitor cells, effectively bridging the window until the long-term engraftment of the single cord blood unit occurs. This dual-phase engraftment profile mitigates the risks of prolonged cytopenias and infectious complications, which historically have hampered cord blood transplantation outcomes.

Beyond survival metrics, the trial data illuminate a substantial reduction in graft-versus-host disease manifestations. GVHD, a potentially fatal complication resulting from donor immune cells attacking recipient tissues, poses a critical barrier in stem cell transplantation. The absence of severe acute or chronic GVHD in this cohort attests to the immunological compatibility benefits intrinsic to cord blood grafts, enhanced by the strategic administration of the expanded progenitor product. This immunomodulatory effect may reflect nuanced interactions at the cellular and molecular levels, warranting further mechanistic investigations.

The patient cohort primarily comprised individuals diagnosed with various leukemias and myelodysplastic syndromes, representing a spectrum of hematologic malignancies with high unmet clinical needs. Most subjects have now reached nearly two years post-transplantation, maintaining robust remission status. One notable instance involved a patient who relapsed nearly a year post-transplant but subsequently achieved remission following additional treatment, underscoring both the potential and limitations inherent in current therapeutic strategies.

This study exemplifies translational research excellence, bridging basic stem cell biology with clinical innovation. The expansion methodology for dilanubicel utilized advanced culture conditions optimizing progenitor proliferation without inducing differentiation or loss of stemness. Such fine-tuned ex vivo manipulation is emblematic of cutting-edge regenerative medicine, harnessing the intrinsic plasticity of cord blood stem cells. Moreover, the collaborative fabric weaving together the Fred Hutch research community and commercial partner Deverra Therapeutics underscores the critical synergy between academia and industry in pioneering new therapeutics.

As with all early-phase clinical trials, cautious optimism is warranted. While these results are promising, larger-scale studies are necessary to validate efficacy, delineate long-term outcomes, and evaluate safety across broader patient populations. The therapy remains investigational, with regulatory approval yet to be secured. However, the implications of enabling more widespread use of cord blood transplants—particularly for patients from ethnically diverse backgrounds who often lack matched donors—are profound, with the potential to democratize access to curative stem cell therapies.

Dr. Milano’s vision includes expanding this therapeutic platform through additional funding avenues, intending to extend these benefits to a larger patient demographic. As the field moves forward, integrating advanced cellular therapies such as pooled, expanded progenitors could reshape the clinical standards for hematopoietic transplantation, balancing efficacy, safety, and accessibility.

This research also raises intriguing scientific questions regarding the mechanisms by which transient progenitor cells facilitate engraftment support and immune homeostasis. Future investigations exploring the molecular signaling pathways, cellular interactions, and niche occupancy may unlock further refinements to optimize transplant protocols.

Ultimately, this pioneering study reaffirms the critical importance of umbilical cord blood as a versatile and potent resource in regenerative medicine. By overcoming historic cellular quantity constraints through innovative cell expansion and pooling strategies, this approach holds promise to deliver enhanced therapeutic outcomes, offering new hope for patients confronting life-threatening blood diseases.

Subject of Research: People

Article Title: Safety and Clinical Outcomes of Pooled Donor, Non-Engrafting Expanded Progenitor Cells in Single-Unit Cord Blood Transplantation

News Publication Date: 27-Apr-2026

Keywords: Cord blood transplantation, hematopoietic stem cells, leukemias, myelodysplastic syndrome, stem cell expansion, graft-versus-host disease, dilanubicel, ex vivo stem cell culture, hematopoietic recovery, clinical trial, regenerative medicine, immunomodulation

The research team harnessed genetically humanized mouse models, engineered to produce human monoclonal antibodies, to target two critical viral proteins: gp350 and gp42. These antigens play an essential role in EBV’s ability to attach to and penetrate human immune cells. By developing a panel of monoclonal antibodies that specifically bind to these viral components, they successfully interrupted the virus’s infection cycle in mice equipped with human immune systems. Their findings, recently published in the distinguished journal Cell Reports Medicine, shed light on a promising path toward preventive interventions against EBV.

EBV employs a unique mechanism to exploit the human immune system, binding to a vast array of B lymphocytes—immune cells that under normal circumstances orchestrate antibody responses. This broad tropism has historically complicated efforts to design neutralizing antibodies that can effectively block infection without provoking adverse immune reactions in patients. The Fred Hutch team overcame this barrier by innovating an experimental platform that integrates human antibody gene repertoires into mice, allowing the precise generation and selection of fully human antibodies devoid of immunogenicity concerns typical of non-human antibody therapies.

Central to the challenge was identifying antibodies that would neutralize the virus without triggering anti-drug antibodies, which often limit the efficacy of biologics derived from animal sources. The gp350 glycoprotein facilitates EBV’s initial binding to the complement receptor type 2 (CR2) on B cells, essentially the gateway to infection. Conversely, gp42 mediates the fusion process that allows EBV to merge with the host cell membrane, completing viral entry. Targeting these two antigens simultaneously offered a multi-faceted blockade to viral invasion.

The extensive antibody discovery campaign yielded two potent monoclonal antibodies against gp350 and eight against gp42. Among these, one antibody targeting gp42 demonstrated remarkable efficacy by completely abrogating infection in a humanized mouse model. Another gp350-targeting antibody conferred partial protection, highlighting the complex nature of EBV’s interaction with host immune cells. These results underscore the importance of precise epitope targeting and affinity optimization in designing next-generation antiviral monoclonals.

This scientific endeavor not only marks a tremendous leap in understanding EBV immunobiology but also validates an innovative platform for antibody discovery broadly applicable to other pathogens with complex immune evasion strategies. As Crystal Chhan, a key investigator and doctoral candidate in the McGuire Lab, articulated, the journey exemplifies how science often ventures into uncharted territory, revealing unexpected discoveries that redefine therapeutic paradigms.

Beyond the conceptual breakthrough, the team delved into structural analyses of antibody-antigen interactions to map vulnerable viral sites amenable to vaccine design. These epitope landscapes provide critical blueprints for rational vaccine engineering, potentially enabling immunogens that elicit similarly protective antibody responses in humans.

The clinical implications of this research bear particular significance for immunocompromised patient populations, notably transplant recipients. Annually, over 128,000 individuals in the United States undergo solid organ or bone marrow transplantation, procedures that require intensive immunosuppressive regimens. Such interventions render patients highly susceptible to EBV reactivation or primary infection, predisposing them to post-transplant lymphoproliferative disorder (PTLD)—an aggressive EBV-driven lymphoma with high morbidity and mortality.

Presently, no targeted prophylactic therapies exist to mitigate EBV-related complications in these vulnerable cohorts. EBV-infected donor cells can transmit latent virus to recipients, while immunosuppression enables latent EBV to replicate unchecked in those previously infected. Pediatric transplant patients are at even greater risk due to a higher likelihood of being EBV-naïve prior to transplantation. The emergence of monoclonal antibody therapies that specifically prevent EBV infection holds transformative potential to improve graft survival, reduce oncogenic complications, and enhance overall clinical outcomes.

Rachel Bender Ignacio, MD, MPH, an infectious disease specialist involved in the study, emphasizes the unmet medical need. She highlights that effective EBV viremia prevention would diminish PTLD rates and reduce reliance on immunosuppressive dose adjustments, which often jeopardize transplant success. The Fred Hutch approach thus aligns with precision medicine goals, offering tailored prophylaxis grounded in molecular virology.

Looking forward, the Fred Hutch scientists envision translating their preclinical findings into therapeutic candidates ready for human trials. They have secured intellectual property rights covering the monoclonal antibodies discovered, and ongoing collaborations with industry partners aim to fast-track development. The envisioned clinical pathway involves initial safety assessments in healthy adults, followed by efficacy trials in immunosuppressed transplant recipients at high EBV risk.

The prospect of delivering an antibody infusion that confers robust, durable protection against one of the most pervasive human viruses represents a paradigm shift in infectious disease management. Andrew McGuire, PhD, reflecting on the journey, remarks that after decades of scientific pursuit, this achievement stands as a beacon of hope for both researchers and patients alike.

As this innovative antibody platform progresses toward clinical application, the broader scientific and medical communities may soon witness a new era in viral prophylaxis—one where rationally designed biologics thwart pathogens once deemed intractable.

In conclusion, this landmark study from Fred Hutch not only offers a viable strategy to combat EBV-associated diseases but also exemplifies how leveraging humanized animal models and monoclonal antibody technology can revolutionize infectious disease therapeutics. The intersection of immunology, virology, and translational science showcased in this work highlights the relentless drive to turn molecular insights into lifesaving interventions.

Subject of Research: Animals
Article Title: Not explicitly stated in the provided text
News Publication Date: 17-Feb-2026
Web References: https://www.fredhutch.org/en.html, https://www.fredhutch.org/en/faculty-lab-directory/mcguire-andrew.html, https://www.linkedin.com/in/crystal-chhan-a909221b5/, https://research.fredhutch.org/mcguire/en.html, https://www.fredhutch.org/en/faculty-lab-directory/bender-ignacio-rachel.html
References: Published in Cell Reports Medicine on 17-Feb-2026
Image Credits: Not specified

Keywords: Antibodies, Viral infections